Key statistics
As of last trade, WAVE Life Sciences Ltd (1U5:DUS) traded at 10.80, 137.89% above the 52 week low of 4.54 set on Apr 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 10.80 |
|---|---|
| High | 10.80 |
| Low | 10.80 |
| Bid | 10.80 |
| Offer | 11.20 |
| Previous close | 10.60 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 182.74m |
| Free float | 157.64m |
| P/E (TTM) | -- |
| Market cap | 2.32bn USD |
| EPS (TTM) | -0.7363 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 15:30 GMT.
More ▼
Announcements
- Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
- Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
- Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
- Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
- Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
- Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
- Wave Life Sciences to Present at Upcoming Investor Conferences
- Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
More ▼
